0001193125-21-043563.txt : 20210216 0001193125-21-043563.hdr.sgml : 20210216 20210216083251 ACCESSION NUMBER: 0001193125-21-043563 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20210216 DATE AS OF CHANGE: 20210216 GROUP MEMBERS: ANSBERT GADICKE GROUP MEMBERS: MPM ONCOLOGY IMPACT MANAGEMENT GP LLC GROUP MEMBERS: MPM ONCOLOGY IMPACT MANAGEMENT LP GROUP MEMBERS: ONCOLOGY IMPACT FUND (CAYMAN) MANAGEMENT L.P. SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: MEI Pharma, Inc. CENTRAL INDEX KEY: 0001262104 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 510407811 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-79594 FILM NUMBER: 21632844 BUSINESS ADDRESS: STREET 1: 11455 EL CAMINO REAL STREET 2: SUITE 250 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: 858-369-7100 MAIL ADDRESS: STREET 1: 11455 EL CAMINO REAL STREET 2: SUITE 250 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: MARSHALL EDWARDS INC DATE OF NAME CHANGE: 20030902 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: UBS Oncology Impact Fund L.P. CENTRAL INDEX KEY: 0001691428 IRS NUMBER: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 450 KENDALL STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-425-9200 MAIL ADDRESS: STREET 1: 450 KENDALL STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 SC 13G/A 1 d125147dsc13ga.htm SC 13G/A SC 13G/A

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)*

 

 

MEI Pharma, Inc.

(Name of Issuer)

Common Stock, par value $0.00000002

(Title of Class of Securities)

55279B202

(CUSIP Number)

December 31, 2020

(Date of Event Which Requires Filing of This Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

 

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

Page 1 of 12

CUSIP No. 55279B202

 

  1.    

  Name of Reporting Persons

 

  UBS Oncology Impact Fund L.P.

  2.  

  Check the Appropriate Box if a Member of a Group (See Instructions)

  (a)  ☐        (b)  ☒

 

  3.  

  SEC USE ONLY

 

  4.  

  Citizenship or Place of Organization

 

  Cayman Islands

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person

With:

 

      5.     

  Sole Voting Power

 

  10,137,859

     6.   

  Shared Voting Power

 

  0

     7.   

  Sole Dispositive Power

 

  10,137,859

     8.   

  Shared Dispositive Power

 

  0

  9.    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  10,137,859

10.  

  Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

 

11.  

  Percent of Class Represented by Amount in Row (9)

 

  9.0%

12.  

  Type of Reporting Person (See Instructions)

 

  PN

 

Page 2 of 12

CUSIP No. 55279B202

 

  1.    

  Name of Reporting Persons

 

  Oncology Impact Fund (Cayman) Management L.P.

  2.  

  Check the Appropriate Box if a Member of a Group (See Instructions)

  (a)  ☐        (b)  ☒

 

  3.  

  SEC USE ONLY

 

  4.  

  Citizenship or Place of Organization

 

  Cayman Islands

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person

With:

 

      5.     

  Sole Voting Power

 

  0

     6.   

  Shared Voting Power

 

  10,137,859*

     7.   

  Sole Dispositive Power

 

  0

     8.   

  Shared Dispositive Power

 

  10,137,859*

  9.    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  10,137,859*

10.  

  Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

 

11.  

  Percent of Class Represented by Amount in Row (9)

 

  9.0%

12.  

  Type of Reporting Person (See Instructions)

 

  PN

 

*

Consists of shares of Common Stock held by UBS Oncology Impact Fund L.P. (“UBS Oncology”). MPM Oncology Impact Management GP LLC (“Oncology GP”) is the general partner of MPM Oncology Impact Management LP (“Oncology LP”), the General Partner of Oncology Impact Fund (Cayman) Management LP (“Oncology Cayman”), the General Partner of UBS Oncology.

 

Page 3 of 12

CUSIP No. 55279B202

 

  1.    

  Name of Reporting Persons

 

  MPM Oncology Impact Management LP

  2.  

  Check the Appropriate Box if a Member of a Group (See Instructions)

  (a)  ☐        (b)  ☒

 

  3.  

  SEC USE ONLY

 

  4.  

  Citizenship or Place of Organization

 

  Delaware

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person

With:

 

      5.     

  Sole Voting Power

 

  0

     6.   

  Shared Voting Power

 

  10,137,859*

     7.   

  Sole Dispositive Power

 

  0

     8.   

  Shared Dispositive Power

 

  10,137,859*

  9.    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  10,137,859*

10.  

  Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

 

11.  

  Percent of Class Represented by Amount in Row (9)

 

  9.0%

12.  

  Type of Reporting Person (See Instructions)

 

  PN

 

*

Consists of shares of Common Stock held by UBS Oncology. Oncology GP is the general partner of Oncology LP, the General Partner of Oncology (Cayman), the General Partner of UBS Oncology.

 

Page 4 of 12

CUSIP No. 55279B202

 

  1.    

  Name of Reporting Persons

 

  MPM Oncology Impact Management GP LLC

  2.  

  Check the Appropriate Box if a Member of a Group (See Instructions)

  (a)  ☐        (b)  ☒

 

  3.  

  SEC USE ONLY

 

  4.  

  Citizenship or Place of Organization

 

  Delaware

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person

With:

 

      5.     

  Sole Voting Power

 

  0

     6.   

  Shared Voting Power

 

  10,137,859*

     7.   

  Sole Dispositive Power

 

  0

     8.   

  Shared Dispositive Power

 

  10,137,859*

9.    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  10,137,859*

10.  

  Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

 

11.  

  Percent of Class Represented by Amount in Row (9)

 

  9.0%

12.  

  Type of Reporting Person (See Instructions)

 

  OO

 

*

Consists of shares of Common Stock held by UBS Oncology. Oncology GP is the general partner of Oncology LP, the General Partner of Oncology (Cayman), the General Partner of UBS Oncology.

 

Page 5 of 12

CUSIP No. 55279B202

 

  1.    

  Name of Reporting Persons

 

  Ansbert Gadicke

  2.  

  Check the Appropriate Box if a Member of a Group (See Instructions)

  (a)  ☐        (b)  ☒

 

  3.  

  SEC USE ONLY

 

  4.  

  Citizenship or Place of Organization

 

  Delaware

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person

With:

 

      5.     

  Sole Voting Power

 

  0

     6.   

  Shared Voting Power

 

  10,137,859*

     7.   

  Sole Dispositive Power

 

  0

     8.   

  Shared Dispositive Power

 

  10,137,859*

9.    

  Aggregate Amount Beneficially Owned by Each Reporting Person

 

  10,137,859*

10.  

  Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

 

11.  

  Percent of Class Represented by Amount in Row (9)

 

  9.0%

12.  

  Type of Reporting Person (See Instructions)

 

  OO

 

*

Consists of shares of Common Stock held by UBS Oncology. Oncology GP is the general partner of Oncology LP, the General Partner of Oncology (Cayman), the General Partner of UBS Oncology. The Reporting Person is the managing director of Oncology GP.

 

Page 6 of 12

Item 1.

 

  (a)

Name of Issuer

MEI Pharma, Inc.

 

  (b)

Address of Issuer’s Principal Executive Offices

11455 El Camino Real

San Diego, CA 92130

 

Item 2.

 

  (a)

Name of Person Filing

UBS Oncology Impact Fund L.P.

Oncology Impact Fund (Cayman) Management LP

MPM Oncology Impact Management LP

MPM Oncology Impact Management GP LLC

Ansbert Gadicke     

 

  (b)

The address of the principal place of business for each of the Filing Persons is c/o MPM Capital LLC, 450 Kendall Street, Cambridge, MA 02142, other than UBS Oncology and Oncology Cayman, whose address is 1st Floor, 2 Hill Street, St Helier, Jersey, JE1 4FS.

 

  (c)

Citizenship

UBS Oncology and Oncology Cayman are organized in the Cayman Islands and Oncology LP and Oncology GP are organized in Delaware. Mr. Gadicke is a United States citizen.

 

  (d)

Title of Class of Securities

Common Stock, par value $0.00000002 per share (“Common Stock”)

 

  (e)

CUSIP Number

55279B202

 

Item 3.

If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable

 

Page 7 of 12

Item 4.

Ownership

 

UBS Entity

    Shares Held
Directly		      Sole Voting
Power		      Shared
Voting
Power		      Sole
Dispositive
Power		      Shared
Dispositive
Power		      Beneficial
Ownership		      Percentage
of Class		  

UBS Oncology

      10,137,859        10,137,859        0        10,137,859        0        10,137,859        9.0 % 

Oncology Cayman(1)

      0        0        10,137,859        0        10,137,859        10,137,859        9.0 % 

Oncology LP(1)

      0        0        10,137,859        0        10,137,859        10,137,859        9.0 % 

Oncology GP(1)

      0        0        10,137,859        0        10,137,859        10,137,859        9.0 % 

Ansbert Gadicke(2)

      0        0        10,137,859        0        10,137,859        10,137,859        9.0 % 

 

(1)

Consists of shares of Common Stock held by UBS Oncology. Oncology GP is the general partner of Oncology LP, the General Partner of Oncology (Cayman), the General Partner of UBS Oncology.

(2)

Consists of shares of Common Stock held by UBS Oncology. The Reporting Person the managing director of Oncology GP.

 

Item 5.

Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

 

Item 6.

Ownership of More than Five Percent on Behalf of Another Person

Not Applicable

 

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

Not Applicable

 

Item 8.

Identification and Classification of Members of the Group

Not Applicable

 

Item 9.

Notice of Dissolution of a Group

Not Applicable

 

Item 10.

Certification

Not Applicable

 

Page 8 of 12

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 11, 2021

 

UBS ONCOLOGY IMPACT FUND, L.P.
By:   Oncology Impact Fund (Cayman) Management L.P.,
  its General Partner
By:   MPM Oncology Impact Management LP,
  Its General Partner
By:   MPM Oncology Impact Management GP LLC
  Its General Partner
By:   /s/ Ansbert Gadicke
Name:   Ansbert Gadicke
Title:   Managing Director
ONCOLOGY IMPACT FUND (CAYMAN) MANAGEMENT L.P.
By:   MPM Oncology Impact Management LP,
  Its General Partner
By:   MPM Oncology Impact Management GP LLC
  Its General Partner
By:   /s/ Ansbert Gadicke
Name:   Ansbert Gadicke
Title:   Managing Director
MPM ONCOLOGY IMPACT MANAGEMENT LP
By:   MPM Oncology Impact Management GP LLC
  Its General Partner
By:   /s/ Ansbert Gadicke
Name:   Ansbert Gadicke
Title:   Managing Director

 

Page 9 of 12

MPM ONCOLOGY IMPACT MANAGEMENT GP LLC
By:   /s/ Ansbert Gadicke
Name:   Ansbert Gadicke
Title:   Managing Director
By:   /s/ Ansbert Gadicke
Name:   Ansbert Gadicke

Exhibits

 

A

Joint Filing Agreement

 

 

Page 10 of 12

EX-99.A 2 d125147dex99a.htm EX-99.A EX-99.A

EXHIBIT A

JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of MEI Pharma, Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.

In evidence whereof, the undersigned have caused this Agreement to be executed on their behalf this 11th day of February, 2021.

 

UBS ONCOLOGY IMPACT FUND, L.P.
By: Oncology Impact Fund (Cayman)
        Management L.P., its General Partner
By: MPM Oncology Impact Management LP,
        Its General Partner
By: MPM Oncology Impact Management GP LLC
        Its General Partner
By:   /s/ Ansbert Gadicke
Name:   Ansbert Gadicke
Title:   Managing Director
ONCOLOGY IMPACT FUND (Cayman) MANAGEMENT L.P.
By: MPM Oncology Impact Management LP,
        Its General Partner
By: MPM Oncology Impact Management GP LLC
        Its General Partner
By:   /s/ Ansbert Gadicke
Name:   Ansbert Gadicke
Title:   Managing Director
MPM ONCOLOGY IMPACT MANAGEMENT LP
By: MPM Oncology Impact Management GP LLC
        Its General Partner
By:   /s/ Ansbert Gadicke
Name:   Ansbert Gadicke
Title:   Managing Director

 

Page 11 of 12

MPM ONCOLOGY IMPACT MANAGEMENT GP LLC
By:   /s/ Ansbert Gadicke
Name:   Ansbert Gadicke
Title:   Managing Director
By:   /s/ Ansbert Gadicke
Name:   Ansbert Gadicke

 

Page 12 of 12